IXICO’s H1 2026 results are the sort of update shareholders were hoping to see. Revenue is growing, the order book is building nicely, gross margin is moving the right way, and the EBITDA loss is narrowing. That is the good bit.
The less comfortable bit is cash. IXICO ended the period with just £1.7 million on hand, which is a lot lower than a year ago, although the £10 million capital raise completed after the period end changes the balance sheet picture quite materially. Put simply, this was a strong trading update paired with a timely fundraise.
IXICO H1 2026 key numbers show revenue growth, margin improvement and a bigger order book
| Metric | H1 2026 | H1 2025 |
|---|---|---|
| Revenue | £3.9 million | £3.2 million |
| Gross profit | £2.1 million | £1.6 million |
| Gross margin | 53.2% | 49.6% |
| EBITDA loss | £0.5 million | £0.7 million |
| Operating loss | £1.6 million | £0.9 million |
| Order book | £18.1 million | £13.1 million |
| Cash | £1.7 million | £5.0 million |
| Loss per share | 1.21p | 1.11p |
IXICO revenue growth in H1 2026 looks solid and, importantly, backed by contract momentum
Revenue rose 23% to £3.9 million, driven by new contract wins, contract extensions and a higher volume of biomarker analysis work. That matters because it suggests this was not a one-off spike. It looks like broader commercial progress across the business.
The order book – meaning signed client contracts not yet delivered – climbed to £18.1 million. That is up 38% year-on-year and 31% since the September 2025 year end. For a services and technology business like IXICO, that is a strong signal that future revenue visibility is improving.
Management also says the order book covers revenue equivalent to 95% of the current market expectation for FY26 revenues. That is a punchy level of coverage for the rest of the year and helps explain why the company says it expects to be at least in line with market expectations for full-year 2026.
Gross margin improvement suggests IXICO is getting better quality revenue, not just more of it
Gross margin improved to 53.2% from 49.6%. That is one of the more encouraging numbers in the release, because margin improvement often tells you more than headline sales growth.
IXICO says this was helped by the relatively fixed nature of delivery costs and a higher proportion of analysis revenues, which are higher margin. It also notes that later-stage trials tend to carry better gross margins, so the more it wins Phase 2 and Phase 3 work, the better the economics could become.
That said, this still needs to flow through consistently. One strong half is useful, but investors will want to see whether this 53.2% gross margin can be held or improved in the second half.
Why IXICO’s operating loss looks worse than the underlying business trend
At first glance, the operating loss looks ugly. It widened to £1.6 million from £0.9 million. On the face of it, that does not scream progress.
But the detail matters here. IXICO says the increase was affected by two items: a change in the treatment of the R&D tax credit and a £0.4 million impairment charge on retired parts of the IXI platform. An impairment is an accounting write-down when older assets are no longer worth what they were carried at.
Strip those effects out, and the adjusted operating loss would have been £0.8 million versus £1.0 million in the prior period. That fits much better with the EBITDA loss improving to £0.5 million from £0.7 million. In plain English, the underlying direction looks better than the statutory operating loss suggests.
IXICO cash fell sharply, but the April 2026 placing takes immediate pressure off
This is the main weak spot in the results. Cash at 31 March 2026 was £1.7 million, down from £3.5 million at the September 2025 year end and £5.0 million a year earlier.
Without fresh funding, that would have been uncomfortable. The company used £1.3 million in operating activities and £0.5 million in investing activities during the half, so the cash burn was real.
The important counterbalance is the post-period capital raise. IXICO completed a £10 million fundraise on 27 April 2026, raising £9.4 million net of fees. Management says this money is for accelerating the TechBio strategy rather than sustaining current operations.
That is a positive message, but investors should still remember that placings come with trade-offs. The dilution details are not disclosed in this RNS, so shareholders will need to look elsewhere for the full impact on share count and ownership.
IXICO TechBio strategy and Medidata partnership could be the bigger long-term story
The most interesting strategic development here is the push to monetise the IXI platform more directly. Instead of only using it inside IXICO’s imaging contract research organisation business, the company wants to license it, integrate it into third-party systems and partner with other service providers.
That is what management means by TechBio. The attraction is obvious: software and platform revenue can potentially be more scalable, more recurring and higher margin than pure services work.
The Medidata agreement is the first real sign that this strategy might have legs. IXICO says IXI will augment Medidata’s clinical trials platform, and Medidata’s services are used in 80% of FDA novel drug approvals. That gives IXICO credibility and distribution into a large ecosystem.
Still, this is the bit where investors should keep their feet on the ground. The RNS does not disclose any revenue contribution from the Medidata collaboration, and it does not set out financial targets for TechBio. So yes, strategically exciting. Financially proven? Not yet.
Alzheimer’s, Parkinson’s and blood-based biomarkers give IXICO more commercial angles
Operationally, IXICO looks to be widening its opportunity set. The company highlighted progress in Alzheimer’s disease and Parkinson’s disease, more later-stage trial wins, and entry into blood-based biomarker validation.
That matters because drug development in neurological disease is complex, specialised and data-heavy. IXICO’s niche is precisely there, using imaging and biomarker analytics to help clinical trials run better and make treatment effects easier to measure.
The appointment of Tanya Voloshen as US-based Chief Commercial Officer also looks sensible. If IXICO wants to scale globally, especially in the US, strengthening the commercial bench is exactly what you would expect.
What retail investors should watch after these IXICO interim results
- Revenue conversion: can the £18.1 million order book keep feeding reported revenue at the current pace?
- Cash discipline: even with £9.4 million net raised, investors should watch burn rates carefully.
- Margin trend: if gross margin stays above 50%, that would support the profitability case.
- TechBio monetisation: partnerships are promising, but actual revenue from licensing or integration is the real test.
- Full-year delivery: management remains focused on 15% revenue growth for FY26 and says it expects to be at least in line with market expectations.
My take on IXICO’s H1 2026 results for shareholders
I think this is a good set of interim results, with one obvious caveat. The core business appears to be improving in a meaningful way: sales are up, margins are better, the order book is strong, and the EBITDA loss is narrowing. That is what progress looks like.
The caveat is that IXICO is still loss-making and, before the April placing, cash had become tight. So this is not a finished turnaround story. It is a company moving in the right direction, but still needing to prove it can turn commercial momentum into durable profitability.
If IXICO can convert its growing order book, keep margins moving higher and show that TechBio partnerships generate real revenue, the investment case gets more interesting from here. For now, I would call this encouraging rather than conclusive.
